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Abstract
Detachment from the extracellular matrix causes apop-
tosis of normal epithelial cells—a phenomenon called
anoikis. K-ras oncogene, an established anoikis in-
hibitor, often occurs in colorectal carcinoma (CRC).
In addition to blocking anoikis-inducing mechanisms,
oncogenic K-ras can cause anoikis-unrelated changes
in CRC cells, such as induction of events promoting
their deregulated mitogenesis, ability to trigger angio-
genesis, and so on. Thus, whether ras-induced anoikis
resistance of CRC cells is essential for their ability to
form tumors in vivo or represents a mere epiphenome-
non is unclear. We found that when poorly tumori-
genic, oncogenic, K-ras–negative, anoikis-susceptible
human CRC cells were cultured under anoikis-inducing
conditions in vitro, they spontaneously gave rise to
an anoikis-resistant cell population harboring de novo
oncogenic K-ras mutations and manifesting dramati-
cally increased tumorigenicity. We further observed
that a variant of the same oncogenic K-ras–negative
anoikis-susceptible cells selected for increased tumori-
genicity acquired de novo oncogenic K-ras mutations
and manifested increased anoikis resistance. Unlike
the case with anoikis, oncogenic K-ras did not rescue
CRC cells from death caused by hypoxia or anticancer
agents. Taken collectively, our results support the no-
tion that ras-induced anoikis resistance of CRC cells is
essential for their ability to form tumors in vivo and
thus represents a potential therapeutic target.
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Introduction
Colorectal carcinoma (CRC) originates from within the
orderly monolayer of the normal intestinal epithelium. Nor-
mal epithelial cells that compose this epithelium are known
to be continuously attached to a form of the extracellular
matrix (ECM) called basement membrane (BM). Detachment
of such cells from the ECM triggers a form of apoptotic cell
death [1,2] often referred to as anoikis [3]. Unlike normal
epithelia, advanced colorectal tumors represent largely disor-
ganized three-dimensional multicellular masses in which cell–
ECM contacts are significantly altered or even disrupted [4–6].
It is known in this regard that carcinoma cells typically grow as
multilayers, and at least some of these cells are detached from
the BM. In addition, cancer cells often secrete BM-degrading
enzymes, which allows tumors to invade adjacent tissues.
Furthermore, in the process of metastatic progression (a series
of events that result in the dissemination and colonization of
malignant cells at ectopic sites), these cells completely detach
from the primary tumor. However, despite the fact that carci-
noma cells are deprived of normal contacts with the BM during
tumor progression—conditions that can be expected to induce
a rapid demise (anoikis) of their normal epithelial counterparts,
a significant fraction of these malignant cells likely remains
viable [5,6]. Although this ability to survive in the absence of
adhesion to the ECM is readily demonstrable in vitro (in
suspension culture), the role of this viability in carcinoma
progression still remains largely inferential, and direct evidence
supporting the critical role of the anoikis resistance of cancer
cells in their ability to form tumors in vivo is lacking.
One line of evidence that is thought to support the in-
volvement of the anoikis resistance of CRC cells in tumor
progression is the fact that the death of intestinal epithelial
cells in suspension culture can be attenuated or aborted by the
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expression of oncogenic ras [7–10], a lesion commonly
found in human CRC [11]. However, it is possible that ras
mutations emerge in this disease for reasons unrelated to
anoikis resistance, such as the need of the respective tumor
cells to be able to proliferate in an uncontrolled manner,
promotion of tumor angiogenesis, or the dependence of
these cells on one of many other changes that are known
to occur in response to Ras activation [12–14]. Establishing
whether ras-induced anoikis resistance contributes to CRC
progression could have important therapeutic implications.
If this resistance does indeed contribute to the progres-
sion of the disease, then targeting the mediators of ras-
dependent antianoikis effect would be expected to create
a situation in which ras-transformed cells can no longer
survive in the absence of adhesion to the ECM and die by
apoptosis. This, in turn, would result not only in the inhibi-
tion of the ability of CRC to survive without being attached
to the ECM but also in the elimination of cells carrying mutant
ras (and hence displaying numerous ras-dependent prop-
erties that drive CRC progression) [12–14] from the CRC
cell population.
Here, we show that culturing K-ras–negative, poorly tu-
morigenic, anoikis-susceptible CRC cells in the absence of
adhesion to the ECM (i.e., under conditions designed to se-
lectively induce anoikis) leads to a spontaneous generation
of a variant of these cells that is anoikis-resistant, harbors
de novo K-ras mutations, and possesses strongly enhanced
tumorigenicity in vivo. We observed that the presence of
mutant K-ras in cancer cells resulted in their increased resis-
tance to anoikis, but not to other forms of cell death, including
that induced by hypoxia or anticancer agents. These data
support the notion that K-ras–dependent inhibition of anoikis
plays an important casual role in CRC progression and,
thereby, may represent a valuable target for cancer therapy
and prevention.
Materials and Methods
Cell Culture
ras knockout derivatives of human CRC-derived cells
(HCT-116, Hkh-2, and Hke-3 cells) have been previously
described [15]. Hkh-2T cells (referred to as Hkh-TUM2 in Yu
et al. [14]) have been previously described [14]. The p53
knockout variant 379.2 of HCT-116 cells was kindly provided
by Dr. Bert Vogelstein (Johns Hopkins University, Baltimore,
MD) [16]. To generate Hkh-2AR cells, 1000 Hkh-2 cells were
cultured in suspension for 72 hours; cells that survived this
treatment were replated in monolayer, allowed to grow for
7 days, and then used for subsequent studies. All cell lines
were cultured in Dulbecco’s modified Eagle’s medium con-
taining 10% fetal bovine serum. For suspension cultures,
cells were plated above a layer of 1% sea plaque agarose
polymerized in Dulbecco’s modified Eagle’s medium.
Soft Agar Colony Formation Assay
A total of 103 cells was suspended in 2 ml of Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum con-
taining 0.3% melted Bacto agar. The resulting suspension
was added to a 60-mm plate covered with a 2-ml layer of
solidified 0.5% Bacto agar in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum. Cell colonies were
allowed to form for 7 to 10 days and counted.
Cell Death Enzyme-Linked Immunosorbent
Assay (ELISA)
Cells growing in monolayer or suspension culture were
removed from the plates and assayed for the presence of
nucleosomal fragments in the cytoplasm by the Cell Death
Detection ELISA kit (Roche Applied Science, Laval, QC,
Canada), according to the manufacturer’s instructions.
K-ras Polymerase Chain Reaction–Restriction Fragment
Length Polymorphism (PCR-RFLP) Analysis
Activating mutations in codon 13 of the K-ras gene were
detected by PCR-RFLP assay, as previously described [14].
Chromosomal DNA was extracted by using a DNeasy tissue
kit (Qiagen, Valencia, CA). PCR was subsequently per-
formed in a reaction volume of 50 ml containing 250 ng of
DNA, 0.2 mM dNTP, 1.5 mM MgCl2, 0.2 mM of each primer,
and 2.5 U of Taq polymerase (Invitrogen, Carlsbad, CA). The
primers used in the reaction were RAS A (sense) 5V-ACTG-
AATATAAACTTGTGGTCCATGGAGCT-3V and RAS B (anti-
sense) 5V-TTATCTGTATCAAAGAATGGTCCTGCACCA-3V.
Amplification reaction consisted of 30 cycles of 94jC for
1 minute, 55jC for 1 minute, and 72jC for 2 minutes. Two
rounds of PCR were performed to obtain a clean 166-bp
product. Then, a 10-ml aliquot of a PCR reaction mixture was
treated with 10 U of XcmI (New England Biolabs, Beverly,
MA) for 20 hours at 37jC, in a total volume of 40 ml. Digestion
products were subsequently detected by electrophoresis in a
3.5% agarose gel. PCR-RFLP analysis of mutations at the
third position of codon 61 of the K-ras gene was performed
as described [17].
Tumorigenicity Assay
A total of 10  106 cells was suspended in 0.2 ml of
phosphate-buffered saline and injected subcutaneously into
the flanks of 8- to 12-week-old female nude athymic BALB/C
mice. The resulting tumors were measured by a vernier
caliper, and tumor volumes were then calculated by using
the formula: a2b/2, where a is width and b is the length of an
ellipsoid tumor perimeter.
Hypoxia Assay
Cells were cultured in a hypoxic chamber (Coy Laboratory
Products, Grass Lake, MI) at < 0.1% oxygen.
Drug-Induced Apoptosis Assay
A total of 103 cells was plated in 60-mm dishes and
subjected to treatment with various concentrations of drugs
for 24 hours. A culture medium was subsequently replaced
with a fresh medium. Cells were then allowed to form
colonies for 7 days, colonies were stained by crystal violet
and counted.
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Results and Discussion
Oncogenic K-ras Is Required for the Anoikis Resistance
of Human CRC Cells
To address the role of oncogenic ras-dependent anoikis
resistance in the ability of human CRC cells to form tumors
in vivo, we chose to study a human CRC cell line (HCT-116)
that carries oncogenic mutation in codon 13 of one of two
K-ras alleles and is highly tumorigenic [15]. In addition,
we used two different isogenic derivatives of HCT-116 cells
(Hkh-2 and Hke-3) [15] in which oncogenic K-ras allele
was disrupted by homologous recombination. Hkh-2 and
Hke-3 cells are poorly tumorigenic [15] and, according to
our studies, display a significantly reduced ability to grow
as colonies in soft agar compared to HCT-116 cells (Figure 1,
A and B). We established that this reduction does not repre-
sent merely a consequence of K-ras–dependent changes in
cellular proliferation because the rate of cell death (anoikis)
in suspension culture, as assayed directly by measuring
chromosomal DNA fragmentation (a characteristic feature
of apoptosis), was significantly increased in the two onco-
genic K-ras–deprived cell lines relative to parental HCT-
116 cells (Figure 1, C and D). It is noteworthy that HCT-116
cells and their mutant K-ras knockout variants are known to
contain an array of additional (and only partially character-
ized) genetic alterations [18,19]. It is therefore remarkable
that the expression of oncogenic K-ras appears to be par-
ticularly critical for the maintenance of the anoikis-resistant
phenotype of these CRC cells irrespectively of coexisting
genetic lesions.
Oncogenic K-ras Is Acquired by Oncogenic
K-ras–Negative CRC Cells Selected for
Increased Resistance to Anoikis
Whether the tumorigenic capacity of CRC cells depends
on their anoikis resistance and whether this resistance is, in
turn, necessarily associated with the presence of oncogenic
K-ras mutations in these cells (of all possible mutations that
Figure 1. Loss of the oncogenic K-ras allele by human colorectal cancer HCT-116 cells renders them anoikis-susceptible. (A and B) CRC-derived HCT-116 cells
and oncogenic K-ras knockout variants of these cells (A, Hkh-2; B, Hke-3) were plated in soft agar or monolayer culture, and colonies formed by the cells were
counted 7 to 10 days later. Results are expressed as a percentage of the number of cells plated in the monolayer. (C and D) HCT-116 and Hkh-2 (C) or Hke-3 (D)
cells were cultured while attached to or detached from the ECM for 24 hours and assayed for apoptosis by cell death ELISA, which detects the presence of
oligonucleosomes in the cytoplasm of apoptotic cells. The levels of apoptosis observed in attached cells were subtracted from the respective numbers obtained in
case of detached cells as background. Results are expressed as a ratio between the apoptotic signal observed for Hkh-2 (C) or Hke-3 (D) cells and that detected in
case of HCT-116 cells. Results represent the average of duplicates (A, B, and D) or triplicates (C) plus the standard deviation. All experiments were repeated twice,
with similar results.
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can, in principle, be acquired by these cells during their
natural history [19]) are not known. To address this question,
anoikis-susceptible Hkh-2 cells were maintained in suspen-
sion culture to enforce the selection for cellular changes
required for the acquisition of anoikis resistance by these
cells and to exclude all other potential influences that could
affect the emergence of oncogenic mutations in CRC cells
in vivo (e.g., inflammation, limited access to oxygen and
nutrients, and so on). We observed that 21.5% of Hkh-2 cells
originally plated in suspension culture (SD = 0.5%; n = 2)
remained clonogenic when replated in monolayer after being
cultured in suspension for 72 hours. We thus established
these anoikis-resistant cells as a cell line (called Hkh-2AR) in
monolayer culture.
We found that Hkh-2AR cells exhibited a stable anoikis-
resistant phenotype on secondary detachment from the ECM
(Figure 2, A and B). We reasoned that these cells likely
harbor permanent de novo–acquired genetic alterations that
could trigger the effects that have been previously observed
due to the presence of mutant K-ras oncogene (Figure 1). In
this regard, we considered two important circumstances.
First, Hkh-2 cells are known to possess a deficient DNA
repair system and, therefore, if necessary, are likely to
undergo secondary mutations [19]. Second, such mutations
could activate proteins that are known to be able to block
anoikis, including K-Ras [9,10] encoded by the wild-type
K-ras allele that is still present in Hkh-2 cells after the dis-
ruption of the oncogenic K-ras allele [15]. Therefore, we car-
ried out an RFLP analysis of the remaining K-ras allele in
Hkh-2AR cells to test whether this allele had acquired an
oncogenic mutation [14]. To this end, a fragment of the K-ras
gene containing codon 13 was amplified by PCR. PCR prim-
ers were designed in such a way that the cleavage site for the
restriction enzyme XcmI would have been created if codon
13 was wild-type, but not if this codon was mutant [14].
Remarkably, a significant fraction of anoikis-resistant Hkh-
2AR cells exhibited the presence of the mutant K-ras allele
(Figure 2C). By contrast, RFLP analysis revealed that neither
HCT-116 nor Hkh-2 or Hkh-2AR cells displayed an A-to-C
or A-to-T mutation of the third base of codon 61 of K-ras
(not shown; the latter mutation was observed by others in a
fraction of colorectal cancers) [20].
To eliminate the possibility that the emergence of the codon
13 mutation of the K-ras gene in Hkh-2AR cells was the
consequence of the carryover of a subpopulation of parental
HCT-116 cells to the population of Hkh-2AR cells that might
have occurred at some point during the natural history of the
latter cells, we took advantage of the fact that HCT-116 cells
are neomycin-susceptible whereas Hkh-2 cells—and con-
sequently Hkh-2AR cells (derived from Hkh-2 cells)—are
neomycin-resistant. This is due to the fact Hkh-2 cells were
generated from HCT-116 cells by the disruption of the mutant
K-ras allele by a cassette containing a neomycin resistance
gene [15]. We thus used RFLP analysis to test Hkh-2AR cells
Figure 2. The population of oncogenic K-ras allele –deprived CRC cells selected for increased anoikis resistance is enriched with cells carrying an oncogenic
mutation of the second K-ras allele. Hkh-2 cells and a variant of these cells (Hkh-2AR) that was selected for increased anoikis resistance were assayed for the
ability to form colonies in soft agar (A) and to undergo anoikis (B), as in Figure 1. Results in (A) and (B) represent the average of the duplicates plus the standard
deviation. Experiments in (A) and (B) were repeated twice, with similar results. (C) Genomic DNA was extracted from Hkh-2 and Hkh-2AR cells, and two rounds of
PCR were performed to obtain a 166-bp product containing the sequence corresponding to codon 13 of K-ras. PCR was treated with XcmI. When codon 13 is wild
type, the PCR product contains a restriction site for XcmI, and digestion yields bands of 138 and 28 bp. If a mutation is present in either of the first two bases of
codon 13, the mutant PCR fragment is not digested by XcmI and remains at its original size of 166 bp. Bands were visualized by electrophoresis in agarose gel.
This experiment was repeated three times with three independently obtained preparations of genomic DNA, with similar results. (D) Hkh-2AR cells were analyzed
as in (C) for the presence of oncogenic mutation in codon 13 of K-ras before () and after (+) treatment with 1.3 mg/ml neomycin for 5 to 7 days. This experiment
was repeated three times with three independently obtained preparations of genomic DNA, with similar results.
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for the presence of K-rasmutation in codon 13 after neomycin
treatment. We reasoned that any HCT-116 cell that might
be present in the population of Hkh-2AR cells should die in
response to neomycin treatment. In this case, the signal cor-
responding to mutant K-ras should no longer be detectable
in neomycin-treated Hkh-2AR cells. We have not observed
any obvious changes in the viability and growth of Hkh-2AR
cells during or after exposure to neomycin, whereas all
HCT-116 cells died as a result of a similar treatment in paral-
lel control experiments. As shown in Figure 2D, exposure to
neomycin did not result in any significant change in the ratio
between the signal corresponding to mutant K-ras and that
corresponding to the wild-type K-ras observed in case of
Hkh-2AR cells. Therefore, the emergence of the codon 13
mutation of K-ras gene in Hkh-2AR cells was not the con-
sequence of the carryover of a subpopulation of parental
HCT-116 cells to the population of Hkh-2AR cells.
Based on the results presented above, we concluded
that the acquisition of anoikis resistance by parental Hkh-2
cells was accompanied by a significant enrichment of a
population of these cells with those that have acquired
a secondary oncogenic mutation in codon 13 of the K-ras
proto-oncogene.
CRC Cells Selected for Increased Resistance to Anoikis
Display Increased Tumorigenicity In Vivo
Whether CRC cells that have acquired increased anoikis
resistance can necessarily be expected to possess an in-
creased tumorigenic potential is not known. In this regard,
we observed that Hkh-2AR cells, but not their parental Hkh-2
counterparts, formed aggressive tumors in immunodeficient
mice with 100% efficiency and within < 2 months of subcu-
taneous tumor cell injection (Figure 3A). We also observed
that the tumorigenicity of Hkh-2AR cells was lower than that
of HCT-116 cells (Figure 3, A and B). This was likely due to
the fact that, unlike HCT-116 cells, all of which harbor mutant
K-ras, only a fraction of Hkh-2AR cells (Figure 2C) carries
oncogenic K-ras mutation.
The observations presented above (Figures 2 and 3A)
lead to at least two important conclusions. First, acquisition
of anoikis resistance by CRC cells is, at least under some
circumstances, sufficient to trigger the attainment of an overt
tumorigenic phenotype by these cells. Second, CRC cells
likely became anoikis-resistant and tumorigenic, at least in
part, due to the acquisition of oncogenic mutations of the
K-ras proto-oncogene gene by these cells.
CRC Cells Selected for Increased In Vivo Tumorigenicity
Display the Presence of De Novo–Acquired Oncogenic
Mutations of K-ras and Increased Resistance to Anoikis
We reasoned that if anoikis resistance is required for the
acquisition of an aggressive tumorigenic phenotype by CRC
cells in vivo, then the CRC cells selected for elevated in vivo
tumorigenicity should display increased anoikis resistance.
To test whether this is the case, we took advantage of our
recent observations indicating that even though Hkh-2 cells
are poorly tumorigenic in vivo, small tumors do arise from
these cells in mice eventually after a long latency period
[14]. We thus established a cell line (called Hkh-2T) from one
of these tumors and demonstrated that the population of
tumor-derived Hkh-2 cells is significantly enriched with cells
carrying the oncogenic mutation of K-ras in codon 13 of the
remaining K-ras allele compared to parental Hkh-2 cells [14].
We have now compared the anoikis resistance of Hkh-2
cells to that of their tumorigenic derivative Hkh-2T. As shown
in Figure 4, A and B, Hkh-2T cells were significantly more
capable of growing anchorage-independently and were sig-
nificantly less susceptible to detachment-induced apoptosis
than their parental Hkh-2 counterparts. Collectively, our ob-
servations enforce the notion that anoikis resistance and
the tumorigenicity of CRC cells are tightly linked (and inter-
dependent) not only at the functional level but also at the
molecular level. Namely, attainment of both of these proper-
ties by CRC cells (at least in our experimental conditions)
is invariably paralleled by (and likely represents the conse-
quence of) the acquisition of oncogenic K-ras mutations by
these cells. It, however, remains to be established whether
the indicated effects of this oncogene pertain to its general
ability to protect CRC cells from cell death, regardless of the
nature of the death-promoting stimulus or whether these
Figure 3. Poorly tumorigenic oncogenic K-ras–deficient variants of CRC cells selected for increased resistance to anoikis display increased tumorigenicity in vivo.
(A) Hkh-2 and Hkh-2AR cells were injected subcutaneously into nude mice, and tumor volumes were measured at indicated time points. (B) Hkh-2 and HCT-116
cells were processed as in (A). The number of mice (n) used in each case is indicated. Bars represent the standard error of the mean. Experiments in (A) and (B)
were repeated twice, with similar results.
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effects are, at least to a degree, unique to death induced by
cell detachment from the ECM.
Oncogenic K-ras Does Not Confer Survival Advantage
to CRC Cells Exposed to Anoikis-Unrelated
Proapoptotic Stimuli
To test whether the effect of oncogenic K-ras on the sur-
vival of CRC cells is relatively unique to anoikis, we chose to
expose HCT-116 cells or their K-ras–disrupted counterparts
to apoptosis-inducing effects of hypoxia (Figure 5) or che-
motherapeutic agents (Figure 6), both of which are highly
relevant to CRC progression and treatment [21–23]. In
particular, tumor hypoxia can arise as a natural consequence
of a disorganized and dysfunctional tumor vasculature [21] or
else result from treatment with antiangiogenic agents, some
of which (bevacizumab) have recently become a front-line
therapy in CRC [24]. These agents restrict tumor perfusion
and oxygen supply and thus cause the apoptotic death of
cancer cells [24,25]. HCT-116 cells appear to represent an
adequate model for studying this therapeutic paradigm in
that exposure to hypoxia in vitro results in a gradual loss of
their clonogenicity (Figure 5). This loss of clonogenicity, how-
ever, was not enhanced by loss of oncogenic K-ras. We
found, in this regard, that the two K-ras–deficient variants of
HCT-116 cells (Hkh-2 and Hke-3) exhibited susceptibility to
hypoxia-induced death similar to that of parental HCT-116
cells (Figure 5). Thus, expression of mutant K-ras appears
to have little effect on the survival of these CRC cells under
hypoxic conditions. Therefore, the status of K-ras cannot
be expected to have a significant impact on the growth of
colorectal tumors under hypoxia and, more importantly,
would not be predictive of the responses of CRC patients
to antiangiogenic therapy, a notion supported by recent clini-
cal evidence [26].
Another relevant inducer of the apoptotic death of CRC
cells is cytotoxic chemotherapy. To this end, we examined
the role of ras in the protection of HCT-116 cells from death-
promoting stimuli, such as those induced by a topoisomer-
ase I inhibitor irinotecan (Camptosar; Pfizer Inc., New York,
NY) and an antimetabolite 5-fluorouracil (5-FU). Both of
these drugs are presently being used in clinics for CRC treat-
ment [22,23]. In addition, we used a cyclooxygenase-2 in-
hibitor sulindac, which is now considered to represent a
prototypic anti-CRC agent [27]. All three chemotherapeutic
drugs are well known to be able to trigger apoptosis [27–29].
As a control for these studies, we used another isogenic
Figure 4. A variant of oncogenic K-ras allele–deprived CRC cells selected
for increased in vivo tumorigenicity (and previously reported to carry an
oncogenic mutation of the second K-ras allele) displays increased anoikis
resistance. Hkh-2 cells and a variant of these cells (Hkh-2T) that was selected
for increased in vivo tumorigenicity were assayed for the ability to form colo-
nies in soft agar (A) and undergo anoikis (B), as in Figure 1. Results in (A)
and (B) represent the average of the duplicates plus the standard deviation.
Experiments in (A) and (B) were repeated twice, with similar results.
Figure 5. Oncogenic K-ras does not protect colorectal cancer cells from hypoxia-induced death. HCT-116, Hkh-2, and Hke-3 cells were cultured under hypoxia for
indicated times. Cells were subsequently cultured under normoxic conditions, and colonies formed by cells that survived after being cultured under hypoxia were
stained with crystal violet 7 to 10 days later and counted. Results are expressed as a percentage of the number of colonies obtained after culturing cells under
normoxia and represent the average of the duplicates plus the standard deviation. This experiment was repeated twice, with similar results.
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variant of HCT-116 cells, called 379.2, in which disruption of
both p53 alleles resulted in resistance to cytotoxic agents, such
as 5-FU [16,30].
As may have been expected based on what has already
been published [30], the survival of p53 knockout cells in
the presence of 5-FU, irinotecan hydrochloride, or sulindac
markedly exceeded that of parental HCT-116 cells (Figure 6).
Unlike the case with p53, the status of mutant K-ras did
not predict the responses of CRC cells to treatment with
the aforementioned anticancer agents. For instance, the
Figure 6. Oncogenic K-ras does not protect colorectal cancer cells from death induced by chemotherapeutic drugs. HCT-116, Hkh-2, and 379.2 cells were treated
with indicated doses of irinotecan hydrochloride (A), 5-FU (B), and sulindac (C) for 24 hours. Cell colonies were then allowed to form for 7 to 10 days, stained with
crystal violet, and counted. Results in (A) to (C) are expressed as a percentage of the number of colonies derived from vehicle-treated cells and represent the
average of the duplicates plus the standard deviation. All experiments were repeated twice, with similar results.
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survival of Hkh-2 cells (deprived of oncogenic K-ras and
carrying intact p53) in the presence of irinotecan or sulindac
was significantly greater than that of parental HCT-116 cells
(Figure 6, A and C). However, Hkh-2 cells displayed sensi-
tivity to 5-FU treatment similar to that of parental HCT-116
cells (Figure 6B). Although these analyses are not intended
to establish the predictive value for the efficiency of CRC
therapy as a function of the presence of K-ras or p53 muta-
tions in a wide context of CRC, they do indicate that, in the
same cellular background, the expression of mutant K-ras
can have dramatically different effects on CRC cell survival,
depending on whether these cells are exposed to conditions
related or unrelated to the induction of anoikis.
Loss of p53 Does Not Enhance the Anoikis Resistance
of Human CRC Cells
In the course of CRC progression, acquisition of activat-
ing mutations of K-ras by malignant cells is often followed by
loss of the p53 tumor-suppressor protein [31]. Given that
p53 is well known to be able to stimulate apoptosis [32], we
decided to test whether loss of p53 can further enhance the
anoikis resistance of HCT-116 cells. As shown in Figure 7, A
and B, the p53 knockout variant of HCT-116 cells, 379.2, dis-
played anoikis resistance similar to that of parental HCT-116
cells. Thus, our data indicate that once CRC cells have ac-
quired oncogenic K-ras and K-ras–dependent anoikis resis-
tance, loss of p53 does not enhance this resistance further.
Our data indicating that the anoikis resistance of CRC
cells tends to depend on the status of K-ras, rather than on
that of p53, are consistent with our previous observations [9]
demonstrating that DLD-1 cells, another CRC-derived cell
line that carries oncogenic K-ras [15], failed to remain
anoikis-resistant after the ablation of the oncogenic K-ras
allele by homologous recombination, even though these
cells do not express functional p53 [9,33]. Furthermore,
despite the absence of functional p53, the resulting onco-
genic K-ras–deprived variants of DLD-1 cells were found
to be incapable of growing in the absence of adhesion to
the ECM as colonies in soft agar (unlike parental DLD-1 cells
that are capable of such growth) [15]. Thus, based on these
data and on our results presented above (Figure 7), it ap-
pears that it is the acquisition of oncogenic ras, rather than
loss of p53, that renders CRC cells anoikis-resistant.
Our study offers several novel observations relevant to
the role of the anoikis resistance of CRC cells in the pro-
gression of the disease. We have demonstrated that en-
forced survival of nontumorigenic intestinal epithelial cells
under anoikis-inducing conditions can lead to the emergence
of de novo K-ras mutations in these cells and renders them
overtly tumorigenic. This is consistent with the notion that
anoikis resistance is a prerequisite of tumor growth and not
just an epiphenomenon. Importantly, we were able to induce
the anoikis resistance of CRC cells in two independent ways,
namely, by forcing these cells to survive in suspension
culture and by forcing them to form tumors in vivo. In both
cases, one genetic lesion that consistently emerged in
resulting cells was the oncogenic mutation of K-ras. This
suggests that, in the context of CRC, this lesion is particularly
efficient in rendering cancer cells anoikis-resistant. Indeed,
K-ras mutations occur with high frequency, mainly during
the early stages of CRC progression [31] and in tumors
that tend to display a three-dimensional, rather than a flat,
growth pattern [34] (i.e., under circumstances where over-
coming anoikis could be especially important).
Our data indicate that anoikis resistance is required
for the ability of CRC cells to form subcutaneous three-
dimensional tumors in mice. Thus, anoikis resistance of car-
cinoma cells may be important not only for their metastatic
potential, as has been previously suggested by others
[5,6], but also for the ability of primary tumors to grow as
disorganized three-dimensional masses in which a signifi-
cant proportion of malignant cells is deprived of proper
contacts with the BM. This possibility is consistent with our
earlier findings. We demonstrated in this regard that ras
oncogene blocks the anoikis of rat and human intestinal
epithelial cells by downregulating a proapoptotic protein
Bak [7] and by upregulating an antiapoptotic protein Bcl-XL
[8]. We also observed that the reversal of the effects of ras
Figure 7. Loss of p53 does not enhance the anoikis resistance of human CRC cells. (A) HCT-116 and a p53 knockout variant of these cells (379.2) were assayed
for the ability to form colonies in soft agar (A) and to undergo anoikis (B), as in Figure 1. Results in (A) and (B) represent the average of the duplicates plus the
standard deviation. Experiments in (A) and (B) were repeated twice, with similar results.
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on Bak and Bcl-XL suppressed the anoikis resistance of
ras-transformed cells and significantly blocked their ability
to form subcutaneous tumors on injection into mice [7,8].
In view of these data, as well as of our findings reported
in the present study, the fact that the frequency of onco-
genic mutations of ras is known to be significantly higher
in three-dimensionally growing colorectal tumors compared
to those growing in a flat manner [34] does not appear to
be coincidental.
What molecular mechanisms could have resulted in sec-
ondary oncogenic K-rasmutations in the tumorigenic Hkh-2T
and anoikis-resistant Hkh-2AR cells that we observed in this
study, as well as in a previous study [14]? It seems possi-
ble that these mutations represent the consequence of the
documented DNA mismatch repair defects of HCT-116 cells
and the subsequent increased rate of spontaneously occur-
ring mutations that have been reported in these cells by
others [19]. According to one likely scenario, a small and
initially undetectable fraction of oncogenic K-ras knockout
Hkh-2 cells could have spontaneously acquired an onco-
genic mutation of the second K-ras allele during their natural
history. The population of Hkh-2 cells containing this on-
cogenic mutation could have received a selective growth/
survival advantage under the pressure existing during tumor
growth in mice and under anoikis-inducing conditions in the
absence of adhesion to the ECM. In addition, it cannot, in
principle, be excluded that the frequency of K-ras mutations
could be increased by the influence of the restrictive condi-
tions themselves. In this regard, hypoxia and hypoglycemia
(not uncommon in the tumor microenvironment) were dem-
onstrated to lead to the downregulation of a key mismatch
repair protein MSH2 in Hkh-2 cells and to the increased
rate of spontaneously occurring mutations in these cells,
including the acquisition of de novo oncogenic mutations of
K-ras [35]. Thus, it is conceivable that conditions existing
during cell growth both in vivo and in the absence of cell
adhesion to the ECM could have triggered mechanisms
resulting in the acquisition of mutant K-ras by the respective
variants of CRC cells.
Our studies indicate that the role of mutant K-ras in the
ability of CRC cells to resist apoptosis depends on the nature
of a proapoptotic stimulus. This is important for at least
two reasons. First, understanding pathways resulting in the
anoikis resistance of CRC cells (in which K-ras is protective)
may offer the opportunity to restore the functionality of these
pathways (downstream of K-Ras) and thus suppress tumor
growth. Second, our data indicate that the susceptibility of
CRC cells to anoikis-promoting treatment may not be abro-
gated by prior exposure to chemotherapy because the re-
sponsiveness of CRC cells to the latter appears to, at least in
our hands, be driven by mechanisms/pathways (oncogenic
K-ras–independent) different from those involved in anoikis
resistance (oncogenic K-ras–dependent).
In summary, our results support the notion that rendering
malignant intestinal epithelial cells anoikis-resistant repre-
sents one of the essential mechanisms by which oncogenic
ras promotes the growth of tumors formed by these cells
in vivo.
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